Without generic competition, the US is at risk of losing its position of leadership in biopharmaceuticals.
Charles E. DiLiberti
Advertisement
Charles E. DiLiberti is vice president of scientific affairs at Barr Laboratories, Inc., 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677, cdiliberti@barrlabs.com.
Articles by Charles E. DiLiberti
Of all the protein products on the US market, at most 75 are likely to become genericized.
Advertisement
Latest Updated Articles
Final Word: The US is Falling Behind on Generic BiopharmaceuticalsPublished: June 1st 2006 | Updated:
The Best Targets for BiogenericsPublished: April 1st 2006 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
